Journal of radiation research · 2026
Comparison of percutaneous and transarterial fiducial marker placement before proton therapy for pancreatic cancer.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shoji Jumpei, Ohta Kengo, Suzuki Kazushi, Horibe Akihiro, Hatano Motoki, Murai Kazuma, Nakajima Koichiro, Iwata Hiromitsu, Ogino Hiroyuki, Hiwatashi Akio
Аннотация
PURPOSE: This study aimed to evaluate the feasibility and safety of percutaneous fiducial marker placement using a 25G needle compared with transarterial placement before proton therapy for pancreatic cancer.
MATERIALS AND METHODS: Patients who underwent fiducial marker placement from 2013 to 2023 were retrospectively reviewed. For percutaneous placement, a 25G needle was used to place markers in or around the tumor under computed tomography (CT) guidance. For transarterial placement, a metal coil was placed as a fiducial marker in a blood vessel near the tumor using a microcatheter. Technical success was defined as the reliable use of the placed fiducial marker throughout the entire proton therapy course. Major complications were defined as grade 3 or higher. Each outcome was compared using Fisher's exact test or the Mann-Whitney U test.
RESULTS: Forty-nine and 60 patients underwent percutaneous and transarterial fiducial marker placement, respectively. The technical success rates were 89.8 and 90.0% for percutaneous and transarterial placement, respectively, with no statistically significant difference between them (P > 0.99). There were no major complications in either case. The median procedure time for percutaneous placement was significantly shorter than that for transarterial placement (3.3 vs 40.0 min; P < 0.001). The median distance between the marker and the tumor was shorter with percutaneous placement than with transarterial placement (0.0 vs 10.0 mm; P = 0.005).
CONCLUSION: Percutaneous placement of fiducial markers for pancreatic cancer proton therapy using a 25G needle could be performed faster than transarterial placement with a high success rate.
MATERIALS AND METHODS: Patients who underwent fiducial marker placement from 2013 to 2023 were retrospectively reviewed. For percutaneous placement, a 25G needle was used to place markers in or around the tumor under computed tomography (CT) guidance. For transarterial placement, a metal coil was placed as a fiducial marker in a blood vessel near the tumor using a microcatheter. Technical success was defined as the reliable use of the placed fiducial marker throughout the entire proton therapy course. Major complications were defined as grade 3 or higher. Each outcome was compared using Fisher's exact test or the Mann-Whitney U test.
RESULTS: Forty-nine and 60 patients underwent percutaneous and transarterial fiducial marker placement, respectively. The technical success rates were 89.8 and 90.0% for percutaneous and transarterial placement, respectively, with no statistically significant difference between them (P > 0.99). There were no major complications in either case. The median procedure time for percutaneous placement was significantly shorter than that for transarterial placement (3.3 vs 40.0 min; P < 0.001). The median distance between the marker and the tumor was shorter with percutaneous placement than with transarterial placement (0.0 vs 10.0 mm; P = 0.005).
CONCLUSION: Percutaneous placement of fiducial markers for pancreatic cancer proton therapy using a 25G needle could be performed faster than transarterial placement with a high success rate.